Management of patients with atrial fibrillation at high risk of stroke: current treatment options

Duncan Edwards, Keara Harris, Jonathan MantPrimary Care Unit, University of Cambridge, Cambridge, UKAbstract: Atrial fibrillation (AF) is common, and is associated with an increased risk of stroke. Patients' absolute risk of stroke depends on the presence or absence of additional risk fa...

Full description

Bibliographic Details
Main Authors: Edwards D, Harris K, Mant J
Format: Article
Language:English
Published: Dove Medical Press 2012-06-01
Series:Research Reports in Clinical Cardiology
Online Access:http://www.dovepress.com/management-of-patients-with-atrial-fibrillation-at-high-risk-of-stroke-a10214
id doaj-65217b08f48e46dd9b630603692c608c
record_format Article
spelling doaj-65217b08f48e46dd9b630603692c608c2020-11-24T23:02:44ZengDove Medical PressResearch Reports in Clinical Cardiology1179-84752012-06-012012default3547Management of patients with atrial fibrillation at high risk of stroke: current treatment optionsEdwards DHarris KMant JDuncan Edwards, Keara Harris, Jonathan MantPrimary Care Unit, University of Cambridge, Cambridge, UKAbstract: Atrial fibrillation (AF) is common, and is associated with an increased risk of stroke. Patients' absolute risk of stroke depends on the presence or absence of additional risk factors as well as AF, including prior thromboembolism, increased age, hypertension, diabetes, structural heart disease, and female sex. The risk to benefit ratio of stroke prevention therapy differs according to the patients' absolute risk. There is evidence that even those with an estimated annual stroke risk of 2%–4%, who were once classified as medium risk, would benefit from anticoagulation and should be included in an expanded high-risk category. Alternatives to anticoagulation include the restoration of sinus rhythm and left atrial appendage surgery, but these may not be suitable for many high-risk patients with comorbidities. Antiplatelets are substantially less effective than anticoagulation and cause similar rates of bleeding. Self-monitoring and computerized decision support increases the time in therapeutic range and effectiveness of vitamin K antagonists. Novel oral anticoagulants including dabigatran, rivoraxaban, and apixaban have been shown to be noninferior to warfarin, do not require monitoring, and increase the prescribing options for stroke prevention in AF.Keywords: stroke prevention, atrial fibrillation, anticoagulants, primary preventionhttp://www.dovepress.com/management-of-patients-with-atrial-fibrillation-at-high-risk-of-stroke-a10214
collection DOAJ
language English
format Article
sources DOAJ
author Edwards D
Harris K
Mant J
spellingShingle Edwards D
Harris K
Mant J
Management of patients with atrial fibrillation at high risk of stroke: current treatment options
Research Reports in Clinical Cardiology
author_facet Edwards D
Harris K
Mant J
author_sort Edwards D
title Management of patients with atrial fibrillation at high risk of stroke: current treatment options
title_short Management of patients with atrial fibrillation at high risk of stroke: current treatment options
title_full Management of patients with atrial fibrillation at high risk of stroke: current treatment options
title_fullStr Management of patients with atrial fibrillation at high risk of stroke: current treatment options
title_full_unstemmed Management of patients with atrial fibrillation at high risk of stroke: current treatment options
title_sort management of patients with atrial fibrillation at high risk of stroke: current treatment options
publisher Dove Medical Press
series Research Reports in Clinical Cardiology
issn 1179-8475
publishDate 2012-06-01
description Duncan Edwards, Keara Harris, Jonathan MantPrimary Care Unit, University of Cambridge, Cambridge, UKAbstract: Atrial fibrillation (AF) is common, and is associated with an increased risk of stroke. Patients' absolute risk of stroke depends on the presence or absence of additional risk factors as well as AF, including prior thromboembolism, increased age, hypertension, diabetes, structural heart disease, and female sex. The risk to benefit ratio of stroke prevention therapy differs according to the patients' absolute risk. There is evidence that even those with an estimated annual stroke risk of 2%–4%, who were once classified as medium risk, would benefit from anticoagulation and should be included in an expanded high-risk category. Alternatives to anticoagulation include the restoration of sinus rhythm and left atrial appendage surgery, but these may not be suitable for many high-risk patients with comorbidities. Antiplatelets are substantially less effective than anticoagulation and cause similar rates of bleeding. Self-monitoring and computerized decision support increases the time in therapeutic range and effectiveness of vitamin K antagonists. Novel oral anticoagulants including dabigatran, rivoraxaban, and apixaban have been shown to be noninferior to warfarin, do not require monitoring, and increase the prescribing options for stroke prevention in AF.Keywords: stroke prevention, atrial fibrillation, anticoagulants, primary prevention
url http://www.dovepress.com/management-of-patients-with-atrial-fibrillation-at-high-risk-of-stroke-a10214
work_keys_str_mv AT edwardsd managementofpatientswithatrialfibrillationathighriskofstrokecurrenttreatmentoptions
AT harrisk managementofpatientswithatrialfibrillationathighriskofstrokecurrenttreatmentoptions
AT mantj managementofpatientswithatrialfibrillationathighriskofstrokecurrenttreatmentoptions
_version_ 1725635376915152896